Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1995-06-07
1999-02-16
Dees, Jose G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
A61K 3156
Patent
active
058721142
ABSTRACT:
Sex steroid precursors such as dehydroepiandrosterone and dehydroepiandrosterone sulphate, and compounds converted in vivo to either of the foregoing, are utilized for the treatment and/or prevention of vaginal atrophy, hypogonadism, diminished libido, osteoporosis, urinary incontinence, ovarian cancer, uterine cancer, skin atrophy, for contraception, and, in combination with an estrogen and/or progestin, for the treatment of menopause. The precursors may be formulated for percutaneous or transmucosal administration. Gels, solutions, lotions, creams, ointments and transdermal patches for the administration of these precursors are provided, as are certain pharmaceutical compositions and kits which can be used for the prevention and treatment of a wide variety of conditions related to decreased secretion of sex steroid precursors by the adrenals.
REFERENCES:
patent: 3472931 (1969-10-01), Stoughton
patent: 3551554 (1970-12-01), Herschler
patent: 3742951 (1973-07-01), Zaffaroni
patent: 3797494 (1974-03-01), Zaffaroni
patent: 3989816 (1976-11-01), Jagannath
patent: 4006218 (1977-02-01), Tibor
patent: 4213978 (1980-07-01), Bodor
patent: 4405616 (1983-09-01), Rajadhyaksha
patent: 4425339 (1984-01-01), Pitchford
patent: 4496556 (1985-01-01), Orentreich
patent: 4518595 (1985-05-01), Coleman
patent: 4542129 (1985-09-01), Orentreich
patent: 4568343 (1986-02-01), Leeper
patent: 4624665 (1986-11-01), Nuwayser
patent: 4666441 (1987-05-01), Andriola
patent: 4812447 (1989-03-01), Roberts
patent: 4835147 (1989-05-01), Roberts
patent: 4956355 (1990-09-01), Prendergast
patent: 4978532 (1990-12-01), El-Rashidy
patent: 5047244 (1991-09-01), Sanvordeker et al.
patent: 5051260 (1991-09-01), Chess
patent: 5064654 (1991-11-01), Berner
patent: 5071644 (1991-12-01), Viegas
patent: 5071657 (1991-12-01), Oloff
patent: 5116828 (1992-05-01), Miura et al.
patent: 5135480 (1992-08-01), Bannon
patent: 5154922 (1992-10-01), Govil
patent: 5162037 (1992-11-01), Whitson
patent: 5362720 (1994-11-01), Labrie
Araki, "Production of Ouariantumors by Hormone Administration," The Kurame Medical Journal, vol. 28, pp. 35-43, 1981.
Rote Liste, Bundesverband Der Pharmazeutischen Industrie E.V. 1992 -Gynodian Depot.
STN International, Karlsruhe File Medline, AN=91262935 G.A. Hauser, 1990.
The Merck Index, 9th Ed., 1976, p. 376, #2846.
Chem Abst. 76: 54671g (1971).
Schwartz, et al., Advances in Cancer Research 51:391-423 (1989).
Gordon, et al., Advances in Enzyme Regulation 26:355-383 (1987).
Parker, et al., Science 208:512 (1980).
Nestler, et al., J. Clin. Endo. and Metab. 66(1):57-61 (1988).
Orentreich, et al., J. Clin. Endo. and Metab. 59(3):551-555 (1984).
Drucker, et al., J. Clin. Endo. and Metab. 35:48-54 (1979).
Welle, et al., J. Clin. Endo. and Metab. 71(5):1259--1264 (1991).
Lacroix, et al., J. Steroidal Biochem. 28(3):317-325 (1987).
Buster, et al., American J. of Obstet. & Gynecol. pp. 1163-1170 (1992).
Barrett-Conner, et al., New Eng. J. Of Med. 315:1519-1524 (1987).
Coleman, et al., Diabetes 33:26-32 (1984).
Sunderland, et al., The Lancet p. 570 (1989).
Regelson, et al., Annal -NY Acad. of Sci. 521:260-273 (1988).
Thoman, et al., Adv. in Immunology 46:221-222 (1989).
Compendium of Patient Information (1983).
Batra, et al., J. Urol., 129(2):418-420 (1983).
Peillon, et al., Ann. Endo., 26(4):419-28 (1965).
Am. J. Nurs., 70:2634 (1970).
Bayliss, et al., An Illustrated Dictionary of Dermatologic Syndromes, Parthenon Publ. Group, NY, 1994, p. 243.
Li, et al., British J. of Cancer, 41:123-129 (1980).
Berne, et al., Physiology, C.V. Mosby Co., St. Louis (1983).
Biological Abstracts, 70:52322 (1980).
Labrie, et al., J. of Clinical Endo. & Metab, 82(8):2403-2409 (1997).
Labrie, et al., J. of Clinical Endo. & Metab, 82(8):2396-2402 (1997).
Labrie, et al., Signal Tranduction in Testicular Cells: Basic and Clinical Aspects, Ernst Schering Research Foundation QWOrkshop, Supplement 2, Ed. Hansson, Springer-Verlag, pp. 185-218 (1996).
Labrie, et al., Steroids, 62:148-158 (1997).
Labrie, et al., N.Y. Academy of Sciences774:16-28 (1995).
Labrie, et al., J. of Clinical Endo. & Metab, 82(10):1-7 (1997).
Luo, et al., Endocrinology, 138(8):3387-3394 (1997).
Labrie, et al., DHEA and Sex Steroids, Society For Endocrinology (1996).
Reynolds, "Martindale The Extra Phamacopoeia" -Prasterone, 29th Edition (1989).
CA, 96:46434c (1982).
Beamer, et al., Cancer Research, 48:2788-2792 (1988).
Marslew, et al., Maturitas, 12:7-16 (1991).
Djerassi, et al., J. Org. Chem., 27:1112 (1962).
Edman, The Menopause, p. 222 (1983).
Ringold, et al., J. Am. Chem. Soc., 78:816 (1956).
Wilson, et al., Williams Textbook of Endocr., pp. 1033-1048 (1992).
Forest, Androgens in Childhood (19):104-120 (1989).
Meunier, et al., Histological heterogeneity . . . treatment, pp. 293-301 (1980).
Bird, Clinical & Investigative Medicine 7(2):119-122 (1984).
Mortola, Journal of Clinical Endo. and Metab. 71(3) (1990).
Roberts, et al., Biological Role of DHEA (1990).
Belisle, et al., Journal of Clinical Endocrinology & Metabolism, 45(3) (1977).
Poulin, et al., Br. Cancer Res. Treat. 13:265-276 (1989).
Haning, Jr., et al., Journal of Clinical Endocrinology & Metabolism, 69(5) (1989).
Abou-Gharbia, et al., J. Pharm. Sci. 73:1643-5 (1984).
Adams, Mol. Cell. Endo. 41:1-17 (1985).
Aloia, et al., Arch. INt. Med. 143:1700-1704 (1984).
Arad, et al., Arteriosclerosis 2:159-166 (1989).
Baran, et al., Calcif. Tissue Res. 26:103-106 (1978).
Belanger, et al., Annals of the NY Acad Sci. 586:93-100 (1990).
Brownsey, B.; Cameron, E. H. D.; Griffiths, K.; Gleave, E. N.; Forrest, A. P. M.; Campbell, H. (1972) Plasma dehydreopiandrosterone sulphate levels in patients with benign and malignant breast disease. Europ. J. Cancer, 8;131-137.
Bulbrook RD; Hayward JL; Spicer CC; Thomas BS (1962) Abnormal excretion of urinary steroids by women with early breast cancer. The Lancet. Dec. 1238-1240.
Bulbrook RD; Hayward JL; Spicer CC; Thomas CS (1962) A comparison between the urinary steroid excretion of normal women and women with advanced breast cancer. The Lancet. Dec. 1235:1240.
Bulbrook RD; Hayward JL; Spicer CC (1971) Relation between urinary androgen and corticoid excretion and subsequent breast cancer. The Lancet. Aug. 395-398.
Bundgaard H (1991) Design and application of prodrugs. In: A textbook of drug design and development (P. Krogsgaard-Larsen, H. Bundgaard, eds), Harwood Academic Publishers GmfH, Chur: Switzerland. pp. 113-191.
Cameron EHD; Griffiths K; Gleave EN; Steward HJ; Forrest APM; Campbell H (1970) Benign and malignant breast disease in south wales: a study of urinary steroids. Br. Med. J. 4:768-771.
Challis JRG; Heap RB (1970) Steroid mono-and diheptafluorobutyrates; preparation, purification and estimation. J. Chromatogr. 50:228-238.
Cleary MP; Zisk J (1983) Effect of dehydroepiandrosterone (DHEA) in adult zucker rats. Fed. Proc. 42:536 (abst. 1433).
Colevard DS; Eriksen EF; Keeting PE; Wilson EM; Lubahn DB; French FS; Riggs BL; Spelsberg TC (1989) Identification of androgen receptors in normal human osteoblast-like cells. Proc. Natl. Acad. Sci. USA 86:854-857.
Dauvois S; Geng CS; Levesque C; Merand Y; Labrie F (1991) Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res. 54:3131-3135.
Deutsch, S.; Benjamin, F.; Seltzer, V.; Tafreshi, M.; Kocheril, G.; Frank, A. (1987) The correlation of serum estrogens and androgens with bone density in the late postmenopause. Int. J. Gynecol. Obstet. 25:217-222.
Drefahl G (1982) Derivatisierung von dextran mit p-Amino-benzoesaure-androstenolonester. Z. Chem. 22:178.
Druzgala et al. (1991) J. Steroid Biochem. Molec. Biol. 38: 149-154.
Edman CD (1983) Estrogen replacement therapy. In: The Menopause Springer Verlag: New York. 6: pp. 77-84.
Eriksen, E. F.; Colvard, D. S.; Berg, N. J.; Graham, M. L.; Mann, K. G.; Spelsbert, C.; Riggs, B. L. (1988) Evidence of estrogen receptors in normal human osterblast-like cells. Science. 241:84-86.
Finkelstein JS; Klibanski A; Neer RM; Greenspan SL; Rosenthal DI; Crowley WF (1987) Osteoporosis in men with idiop
Cebulak Mary C.
Dees Jos,e G.
Endorecherche Inc.
LandOfFree
Therapeutic methods and delivery systems utilizing sex steroid p does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic methods and delivery systems utilizing sex steroid p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic methods and delivery systems utilizing sex steroid p will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2062659